AAAAAA

   
Results: 1-15 |
Results: 15
Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients
Authors: Misset, JL Vennin, P Chollet, P Pouillart, P Laplaige, P Frobert, JL Castera, D Fabro, M Langlois, D Cortesi, E Lucas, V Gamelin, E Laadem, A Otero, J
Citation: Jl. Misset et al., Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients, ANN ONCOL, 12(10), 2001, pp. 1411-1415
Evidence-based medicine: towards evidence-based radiology
Authors: Taieb, S Vennin, P
Citation: S. Taieb et P. Vennin, Evidence-based medicine: towards evidence-based radiology, J RADIOLOG, 82(8), 2001, pp. 887-890
Patient choice for cancer treatment: towards a shared-decision model?
Authors: Vennin, P Taieb, S Carpentier, P
Citation: P. Vennin et al., Patient choice for cancer treatment: towards a shared-decision model?, B CANCER, 88(4), 2001, pp. 391-397
About standard: from rule to patient. Breast cancer as an example
Authors: Vennin, P Taieb, S Carpentier, P
Citation: P. Vennin et al., About standard: from rule to patient. Breast cancer as an example, B CANCER, 88(2), 2001, pp. 221-222
Surgical staging of early invasive epithelial ovarian rumors
Authors: Leblanc, E Querleu, D Narducci, F Chauvet, MP Chevalier, A Lesoin, A Vennin, P Taieb, S
Citation: E. Leblanc et al., Surgical staging of early invasive epithelial ovarian rumors, SEM SURG ON, 19(1), 2000, pp. 36-41
Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovariancancer
Authors: Gore, M Huinink, WT Carmichael, J Gordon, A Davidson, N Coleman, R Spaczynski, M Heron, JF Bolis, G Malmstrom, H Malfetano, J Scarabelli, C Vennin, P Ross, G Fields, SZ
Citation: M. Gore et al., Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovariancancer, J CL ONCOL, 19(7), 2000, pp. 1893-1900
Tamoxifen adjuvant treatment duration in early breast cancer: Initial results of a randomized study comparing short-term treatment with long-term treatment
Authors: Delozier, T Spielmann, M Mace-Lesec'h, J Janvier, M Hill, C Asselain, B Julien, JP Weber, B Mauriac, L Petit, JC Kerbrat, P Malhaire, JP Vennin, P Leduc, B Namer, M
Citation: T. Delozier et al., Tamoxifen adjuvant treatment duration in early breast cancer: Initial results of a randomized study comparing short-term treatment with long-term treatment, J CL ONCOL, 18(20), 2000, pp. 3507-3512
Evaluation of toxicity and efficacy of Re-186-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer
Authors: Kolesnikov-Gauthier, H Carpentier, P Depreux, P Vennin, P Caty, A Sulman, C
Citation: H. Kolesnikov-gauthier et al., Evaluation of toxicity and efficacy of Re-186-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer, J NUCL MED, 41(10), 2000, pp. 1689-1694
Disclosure to the family of breast/ovarian cancer genetic test results: Patient's willingness and associated factors
Authors: Julian-Reynier, C Eisinger, F Chabal, F Lasset, C Nogues, C Stoppa-Lyonnet, D Vennin, P Sobol, H
Citation: C. Julian-reynier et al., Disclosure to the family of breast/ovarian cancer genetic test results: Patient's willingness and associated factors, AM J MED G, 94(1), 2000, pp. 13-18
Predictive value of preoperative abdominopelvic CT for optimal cytoreduction surgery in ovarian carcinoma
Authors: Taieb, S Bonodeau, F Leblanc, E Vennin, P Fournier, C Besson, P
Citation: S. Taieb et al., Predictive value of preoperative abdominopelvic CT for optimal cytoreduction surgery in ovarian carcinoma, B CANCER, 87(3), 2000, pp. 265-272
Thoughts on standards, options and recommendations for hormone replacementtherapy in the case of non-metastatic breast cancer
Authors: Vennin, P
Citation: P. Vennin, Thoughts on standards, options and recommendations for hormone replacementtherapy in the case of non-metastatic breast cancer, B CANCER, 87(12), 2000, pp. 948-950
Cancer genetic consultation and anxiety in healthy consultees
Authors: Julian-Reynier, C Eisinger, F Chabal, F Aurran, Y Bignon, YJ Machelard-Roumagnac, M Maugard, C Nogues, C Vennin, P Sobol, H
Citation: C. Julian-reynier et al., Cancer genetic consultation and anxiety in healthy consultees, PSYCHOL HEA, 14(3), 1999, pp. 379-390
Results of a European organization for research and treatment of cancer/early clinical studies group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix
Authors: Lhomme, C Fumoleau, P Fargeot, P Krakowski, Y Dieras, V Chauvergne, J Vennin, P Rebattu, P Roche, H Misset, JL Lentz, MA Van Glabbeke, M Matthieu-Boue, A Mignard, D Chevallier, B
Citation: C. Lhomme et al., Results of a European organization for research and treatment of cancer/early clinical studies group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix, J CL ONCOL, 17(10), 1999, pp. 3136-3142
A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: A French Anticancer Federation study
Authors: Lhomme, C Vennin, P Callet, N Lesimple, T Achard, JL Chauvergne, J Luporsi, E Chinet-Charrot, P Coudert, B Couette, JE Guastalla, JP Lebrun, D Ispas, S Blumberg, J
Citation: C. Lhomme et al., A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: A French Anticancer Federation study, GYNECOL ONC, 75(2), 1999, pp. 187-193
Novel indications for BRCA1 screening using individual clinical and morphological features
Authors: Eisinger, F Nogues, C Guinebretiere, JM Peyrat, JP Bardou, VJ Noguchi, T Vennin, P Sauvin, R Lidereau, R Birnbaum, D Jacquemier, J Sobol, H
Citation: F. Eisinger et al., Novel indications for BRCA1 screening using individual clinical and morphological features, INT J CANC, 84(3), 1999, pp. 263-267
Risultati: 1-15 |